phase IIIb
Showing 1 - 25 of >10,000
Influenza Trial (Baloxavir Marboxil)
Not yet recruiting
- Influenza
- Baloxavir Marboxil
- (no location specified)
Oct 17, 2023
Spinal Muscular Atrophy Trial (OAV101)
Recruiting
- Spinal Muscular Atrophy
- OAV101
-
Montreal, Quebec, Canada
- +1 more
Jan 31, 2023
Polycythemia Vera Trial (Ropeginterferon alfa-2b-njft (P1101))
Not yet recruiting
- Polycythemia Vera
- Ropeginterferon alfa-2b-njft (P1101)
- (no location specified)
Jul 28, 2022
HIV Trial (CAB LA)
Not yet recruiting
- HIV Infections
- CAB LA
- (no location specified)
Nov 21, 2023
Non-Muscle- Invasive Bladder Cancer Trial (Durvalumab, BCG)
Not yet recruiting
- Non-Muscle- Invasive Bladder Cancer
- Durvalumab
- BCG
- (no location specified)
Jul 5, 2023
Epidemic Meningitis Trial (MCV4, MSPV4)
Not yet recruiting
- Epidemic Meningitis
- MCV4
- MSPV4
- (no location specified)
Aug 21, 2023
NSCLC Trial in Guangzhou (PLB1001)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Aug 15, 2023
Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- (no location specified)
Sep 27, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer Trial (Sacituzumab govitecan)
Not yet recruiting
- Triple Negative Breast Cancer
- Metastatic Breast Cancer
- Sacituzumab govitecan
- (no location specified)
Jan 23, 2023
NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)
Recruiting
- Non-small Cell Lung Cancer
- SH-1028 tablets
- Placebo SH-1028 tablets
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 6, 2023
NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Befotertinib + Icotinib placebo
- Icotinib + Befotertinib placebo
-
Beijing, China
- +2 more
Sep 20, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Mesa, Phoenix (Faricimab PFS Configuration)
Completed
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Faricimab PFS Configuration
-
Mesa, Arizona
- +2 more
Jan 2, 2023
Asthma Trial (BDA MDI, AS MDI)
Not yet recruiting
- Asthma
- BDA MDI
- AS MDI
- (no location specified)
Aug 15, 2022
Allergic Rhinoconjunctivitis, Birch Pollen Allergy Trial (STALORAL® Birch 300 IR)
Not yet recruiting
- Allergic Rhinoconjunctivitis
- Birch Pollen Allergy
- STALORAL® Birch 300 IR
- (no location specified)
Dec 20, 2022
Seasonal Allergic Rhinitis Trial in Kingston (Fexofenadine, Placebo)
Recruiting
- Seasonal Allergic Rhinitis
- Fexofenadine
- Placebo
-
Kingston, Ontario, CanadaInvestigational Site Number :1240001
Jan 29, 2023
Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)
Not yet recruiting
- Unresectable Lung Non-Small Cell Carcinoma
- serplulimab plus chemotherapy as conversion treatment
- (no location specified)
Apr 27, 2023
Melanoma Trial in Wollstonecraft, Cairns (tigilanol tiglate)
Recruiting
- Melanoma
- tigilanol tiglate
-
Wollstonecraft, New South Wales, Australia
- +2 more
Oct 6, 2022
Respiratory Syncytial Virus Infections Trial (Nirsevimab)
Not yet recruiting
- Respiratory Syncytial Virus Infections
- (no location specified)
Jun 24, 2022
Melanoma Trial in Salt Lake City (Nivolumab, HF10)
Terminated
- Melanoma
-
Salt Lake City, UtahHuntsman Cancer Institute
Jun 9, 2022
Unresectable Stage IIIB-IV Malignant Melanoma Trial in Japan (Talimogene laherparepvec)
Completed
- Unresectable Stage IIIB-IV Malignant Melanoma
- Talimogene laherparepvec
-
Nagoya-shi, Aichi, Japan
- +8 more
Jan 13, 2023
Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological
Completed
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Laboratory Biomarker Analysis
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 14, 2022